The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results